165 related articles for article (PubMed ID: 15197951)
1. [Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Ishikawa N; Miyata T; Kurokawa K
Nihon Rinsho; 2004 May; 62 Suppl 5():389-92. PubMed ID: 15197951
[No Abstract] [Full Text] [Related]
2. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Nangaku M; Miyata T; Sada T; Mizuno M; Inagi R; Ueda Y; Ishikawa N; Yuzawa H; Koike H; van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms.
Miyata T; van Ypersele de Strihou C; Ueda Y; Ichimori K; Inagi R; Onogi H; Ishikawa N; Nangaku M; Kurokawa K
J Am Soc Nephrol; 2002 Oct; 13(10):2478-87. PubMed ID: 12239236
[TBL] [Abstract][Full Text] [Related]
4. [Aminoguanidine and other AGE inhibitors].
Kawakami M; Kuroki M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():601-5. PubMed ID: 12387057
[No Abstract] [Full Text] [Related]
5. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Nagai Y; Yao L; Kobori H; Miyata K; Ozawa Y; Miyatake A; Yukimura T; Shokoji T; Kimura S; Kiyomoto H; Kohno M; Abe Y; Nishiyama A
J Am Soc Nephrol; 2005 Mar; 16(3):703-11. PubMed ID: 15647337
[TBL] [Abstract][Full Text] [Related]
6. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Zheng F; Zeng YJ; Plati AR; Elliot SJ; Berho M; Potier M; Striker LJ; Striker GE
Kidney Int; 2006 Aug; 70(3):507-14. PubMed ID: 16775596
[TBL] [Abstract][Full Text] [Related]
7. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF; Franks AM
Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Ceriello A; Motz E
N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779
[No Abstract] [Full Text] [Related]
9. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
Takai S; Miyazaki M
Am J Cardiovasc Drugs; 2006; 6(6):363-6. PubMed ID: 17192125
[TBL] [Abstract][Full Text] [Related]
10. Potential new therapeutic agents for diabetic kidney disease.
Turgut F; Bolton WK
Am J Kidney Dis; 2010 May; 55(5):928-40. PubMed ID: 20138415
[TBL] [Abstract][Full Text] [Related]
11. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
12. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Koga K; Yamagishi S; Takeuchi M; Inagaki Y; Amano S; Okamoto T; Saga T; Makita Z; Yoshizuka M
Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan medoxomil.
Warner GT; Jarvis B
Drugs; 2002; 62(9):1345-53; discussion 1354-6. PubMed ID: 12076183
[TBL] [Abstract][Full Text] [Related]
14. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Ishii M
Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
[TBL] [Abstract][Full Text] [Related]
15. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
[No Abstract] [Full Text] [Related]
16. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Williams ME
Curr Diab Rep; 2004 Dec; 4(6):441-6. PubMed ID: 15539009
[TBL] [Abstract][Full Text] [Related]
18. New potential agents in treating diabetic kidney disease: the fourth act.
Williams ME
Drugs; 2006; 66(18):2287-98. PubMed ID: 17181372
[TBL] [Abstract][Full Text] [Related]
19. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
Elseweidy MM; Elswefy SE; Younis NN; Zaghloul MS
Exp Biol Med (Maywood); 2013 Aug; 238(8):881-8. PubMed ID: 23970406
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; Tibiriçá E
Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
